Multiple sclerosis

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

Retrieved on: 
пятница, мая 31, 2024
Patient, CMSC, Therapy, Multiple sclerosis, MD, RMS, Publication, Harbor

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.

Key Points: 
  • NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.
  • Presentations are now public and can be viewed using the below links.
  • of California San Francisco, San Francisco, CA
    Lead Author: Riley Bove, MD - UCSF Weill Institute of Neurosciences, Dept.
  • of California San Francisco, San Francisco, CA
    Presentations are available on the Publications page, located within the Pipeline section, of the Company’s website at https://www.tgtherapeutics.com/publications/ .

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

Retrieved on: 
четверг, мая 30, 2024
Patient, CMSC, Organization, Mass, Mass General Brigham, Tiziana, Foralumab, FDA, DSM-IV codes, Multiple sclerosis, Cone Health Women's Hospital, Research, Neurology, Fatigue, Multiple sclerosis research, Hospital, MFIS, Pharmaceutical industry

The award ceremony will take place on May 30, 2024 at the Consortium of Multiple Sclerosis Centers annual meeting being held in Nashville, Tennessee.

Key Points: 
  • The award ceremony will take place on May 30, 2024 at the Consortium of Multiple Sclerosis Centers annual meeting being held in Nashville, Tennessee.
  • “We are thrilled to see Dr. Howard Weiner recognized with the ‘Giants of MS’ award for his exceptional achievements in MS research,” said Gabriele Cerrone, Chairman, acting CEO, and founder of Tiziana Life Sciences.
  • Weiner's relentless pursuit of scientific excellence and commitment to improving patient outcomes also exemplifies the values we uphold at Tiziana.
  • This award acknowledges individuals who have demonstrated extraordinary leadership and innovation in the field of MS research.

Hope Biosciences Research Foundation Announces Topline Results of Cell Therapy Clinical Trial in Long COVID

Retrieved on: 
пятница, мая 31, 2024
Stem Cells, Biotechnology, FDA, Health, Philanthropy, General Health, Research, Foundation, Science, COVID-19, Clinical Trials, Patient, Lupus, Visual analogue scale, Ataxia, Cerebral palsy, Muscular dystrophy, Palliative care, Doctor of Philosophy, Stroke, ALS, Placebo, Protocol, Multiple sclerosis, Primary lateral sclerosis, Pancreatic cancer, Hemispherectomy, Polyneuropathy, COVID, Fatigue, B cell, PLS, Central nervous system, Pharmaceutical industry

Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares topline results of a randomized, placebo-controlled Phase II study ( NCT05126563 ) to evaluate Hope Biosciences’ adipose‑derived allogeneic mesenchymal stem cell therapy (HB-adMSCs) for patients with Post‑COVID‑19 syndrome.

Key Points: 
  • Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares topline results of a randomized, placebo-controlled Phase II study ( NCT05126563 ) to evaluate Hope Biosciences’ adipose‑derived allogeneic mesenchymal stem cell therapy (HB-adMSCs) for patients with Post‑COVID‑19 syndrome.
  • The trial enrolled 79 participants, with 39 subjects in the treatment group and 40 in the placebo group; 34 participants completed the study from the treatment group, and 30 from the placebo group.
  • The 26-week study mandated four infusions of 200 million stem cells, for a total of 800 million cells.
  • The study announced in this release is made possible in part due to support from The John S. Dunn Foundation.

Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases

Retrieved on: 
среда, мая 29, 2024
Neuroscience, FDA, Drug development, Pediatrics, Drug discovery, Distinguishing, Mental health, Research, Therapy, ALS, Pharmacology, Human, Translational research, Ageing, Multiple sclerosis, Myenteric plexus, CNS, Division, Cognition, University, Clinical trial, DSM-IV codes, Regulatory affairs, Genetics, Associate, SAB, Schizophrenia, CIAS, Patient, Organization, NIMH, Duke University Hospital, Biomarker, Abstract, Brain, Deficit spending, Pharmaceutical industry

NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB).

Key Points: 
  • NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB).
  • "At Kynexis, we are committed to restoring brain function to enable a better life for people with schizophrenia,” said Kees Been, Chief Executive Officer at Kynexis.
  • Robert Schwarcz, Ph.D., is a Scientific Co-founder of Kynexis and Professor of Psychiatry, Pharmacology and Pediatrics at the University of Maryland Baltimore.
  • Based on these insights, he co-founded Kynexis to develop fundamentally new interventions for the prevention and treatment of brain dysfunctions in humans.

Octave® Bioscience, Inc. Announces Publication in Nature Communications

Retrieved on: 
среда, мая 29, 2024
Health, Communications, Neurology, Research, Science, Publishing, Biotechnology, ACP, EPIC, Patient, Prognosis, UCSF, Nature, Nature Communications, Protein, University, Diagnosis, Disease, Multiple sclerosis, MD, Brigham and Women's Hospital, Harvard Medical School, Biomarker, Manuscript, Hospital, Lead, Medical imaging

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.

Key Points: 
  • Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.
  • Octave’s studies featured in the manuscript included world-class cohorts including CLIMB from Brigham and Women’s, EPIC from UCSF, and the Accelerated Cure Project Biorepository.
  • This work preceded and made possible the analytical and clinical validation studies for Octave’s multi-protein biomarker test, Multiple Sclerosis Disease Activity (MSDA), which were both previously published.
  • In addition, the research indicates multi-protein models have stronger associations than any single protein models.

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
среда, мая 29, 2024
Human services, Partnership, BIIB, Patient, Medicare, Friedreich's ataxia, News, Risk, Food, Medicaid, FDA, Telephone, Person, Conference, Publication, Multiple sclerosis, Traction, EPS, Alzheimer's disease, Defendant, Acquisition, United States congressional committee, GAAP, Court, P.C, Eisai, FY, Physician, District court, DOJ, Complaint, Pharmaceutical industry

Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Biogen is a global biopharmaceutical company that discovers, develops, and delivers therapies for people living with serious and complex diseases worldwide.
  • Biogen's sales of its MS-related products have historically accounted for the majority of the Company's product revenues.
  • Accordingly, because AD-related treatments represented a lucrative market for Biogen, the Company's AD-related products were particularly important to Defendants and investors throughout the Class Period.

BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline

Retrieved on: 
вторник, мая 28, 2024
BIIB, Biogen, Action Replay, News, Advertising, Multiple sclerosis, EPS, Court, FY, District court, Complaint, Security (finance)

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Biogen Inc. (NASDAQ: BIIB)?
  • If you purchased or acquired Biogen securities, and/or would like to discuss your legal rights and options please visit Biogen Inc.
  • If you purchased or acquired Biogen securities, and/or would like to discuss your legal rights and options please visit Biogen Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Wistar Research Identifies Mechanisms for Selective Multiple Sclerosis Treatment Strategy

Retrieved on: 
вторник, мая 28, 2024
Wistar, EBV, PML, Bangladesh Technical Education Board, Phenotype, Nature Microbiology, Nervous system, Patient, Data collection, Wistar Institute, TAF, Sclerosis, Immune system, Travel, FOXP1, Disease, DSM-IV codes, Multiple sclerosis, Epstein–Barr virus infection, SLCL, Liebermann, Neuron, Collaborative writing, Gene, Immortalised cell line, Cell, Manuscript, IL-6, Brain, Inflammation, R01, Vaccine

Though researchers know that EBV can contribute to the development of MS, the exact mechanisms by which it does so aren’t completely understood.

Key Points: 
  • Though researchers know that EBV can contribute to the development of MS, the exact mechanisms by which it does so aren’t completely understood.
  • As a whole, the group’s findings suggested a mechanism of lytic EBV in MS that promoted inflammation and disease.
  • TAF also significantly reduced the expression of inflammatory cytokines like IL-6 in the SLCLs from the patients with active MS.
  • The funders had no role in study design; data collection and analysis; decision to publish; or preparation of the manuscript.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

Retrieved on: 
вторник, мая 28, 2024
Partnership, BIIB, Medicare, News, Risk, Medicaid, Biogen, FDA, Prior, Ext, Defendant, United States congressional committee, LLP, Court, FY, District court, Complaint, Publication, Conference, Multiple sclerosis, Traction, Action Replay, Physician, Human services, Food, EPS, Pomerantz, Patient, Person, Acquisition, Eisai, Pharmaceutical industry

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) and certain officers.

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) and certain officers.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Biogen is a global biopharmaceutical company that discovers, develops, and delivers therapies for people living with serious and complex diseases worldwide.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

Retrieved on: 
вторник, мая 28, 2024
Patient, CMSC, Abstract (summary), Therapy, Multiple sclerosis, MD, RMS, Publication, Harbor

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee.

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee.
  • Abstracts are now available online and can be accessed on the CMSC meeting website at www.mscare.org/2024 or by clicking on the following link: https://meridian.allenpress.com/ijmsc/article/26/s1/1/500896/Abstracts-f... .
  • of California San Francisco, San Francisco, CA
    Lead Author: Riley Bove, MD - UCSF Weill Institute of Neurosciences, Dept.
  • of California San Francisco, San Francisco, CA
    Presentations will be available on the Publications page, located within the Pipeline section, of the Company’s website at https://www.tgtherapeutics.com/publications/ .